No Data
No Data
NanJing Medical Plans to Issue Up to 6 Billion Yuan in Ultra Short-Term Bonds
NanJing Medical's (SHA:600713) plans to issue ultra-short-term bonds worth up to 6 billion yuan, according to a Monday filing with the Shanghai bourse. The bonds shall have an issuance period of up to
Express News | Six companies issued announcements related to share repurchases. Hisense Video has repurchased 351 million yuan of company shares
These 4 Measures Indicate That NanJing Pharmaceutical (SHSE:600713) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Zhitong A Share Sale Restriction and Release List | February 2
According to the Zhitong Finance App, the ban on restricted shares of 8 listed companies was lifted on February 2, with a total market value of about 9.146 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, number of banned shares, Xiamen, Xiangyu, 6000 57, share incentives, 5.3721 million, Nanjing Pharmaceutical, 600,713, share incentives, 5.2482 million, Supor 002032, share incentives, 555,800 Zijin Mining, 601,999 equity incentives, limited sales and circulation, 321.17 million, energy-saving wind power 60,117 million, energy-saving wind power, 601016 share incentives, limited sale and circulation of 8.033,500 Tianwei Food
Express News | The ban on restricted shares with a market capitalization of 8.955 billion yuan was lifted today. Huitai Medical lifted the ban and ranked first with a market value of 8.461 billion yuan
[BT Financial Report Momentary Analysis] Nanjing Pharmaceutical's 2023 Quarterly Report: Asset Growth and Cash Flow Challenges Under Steady Operation
As an important participant in the pharmaceutical distribution industry, Nanjing Pharmaceutical Co., Ltd. (stock code: 600713) directly serves the national medical and health industry. The company's business covers the procurement, warehousing, management and sale of pharmaceuticals and medical equipment, and is supervised by various national departments such as the Ministry of Commerce. Within the industry, Nanjing Pharmaceutical not only actively participated in the activities of industry self-regulatory organizations, but also continued to contribute to the development of the pharmaceutical distribution field. In terms of assets and liabilities, Nanjing Pharmaceutical's 2023 three-quarter report shows that the company's total assets increased from 31,651 billion yuan at the end of the previous year to 33.203 billion yuan, an increase
No Data